Document is current
Any future updates will be listed below
-
Authors
Alexoff, David https://orcid.org/0000-0002-0612-1239
Wong, Dean F.
Kuwabara, Hiroto
Dannals, Robert F.
Ploessl, Karl
Kung, Hank F.
-
Funding
Funding for this research was provided by:
Five Eleven Pharma Inc (Five Eleven Pharma Inc)
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 15 June 2025
First Online: 22 June 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the institutional review boards at Johns Hopkins Medicine (IRB# 00147896) and complied with the Health Insurance Portability and Accountability Act (HIPAA). Written informed consent was obtained for each enrolled subject.
: Not applicable.
: Five Eleven Pharma Inc. is the sponsor of this study. Authors D.A. and K.P. are employees of Five Eleven Pharma and H.F.K. is the founder of Five Eleven Pharma, which holds the patent rights for D3FSP (P16-129) and related technology. D.F.W. is a paid consultant for Engrail Pharmaceuticals, LB Pharma Technologies (via WUSTL), and has contracts (WUSTL) with Eisai, Roche, and Intracellular Technologies. Other authors have no conflicts of interest or relevant financial activities to disclose.
